FDA
-
-
-
-
-
-
-
Cerevel Therapeutics (CERE) Prices 19.73M Share Offering at $22.81/sh
-
-
-
-
-
-
-
Cerevel Therapeutics Holdings (CERE) Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer
-
-
-
-
-
-
-
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
-
-
-
-
-
-
-
Cerevel Therapeutics (CERE) Reports Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
-
-
-
-
-
-
-
Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
-
-
-
-
-
-
-
Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
-
-
-
-
-
-
-
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

